Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?

Summary, in English

Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day + 100. Seventeen patients achieved > 90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with <= 90% donor T-cell engraftment, they showed favorable PFS at 1 year (82% vs. 33%, p = 0.002) and better long-term PFS and OS (p = 0.002 and 0.046, respectively). Donor T-cell engraftment of > 90% at 3 months after RIC allo-SCT for CLL seems to predict favorable short-term and long-term outcome.

• Author: Maciej Machaczka; Jan-Erik Johansson; Mats Remberger; Helene Hallbook; Claes Malm; Vladimir Lazarevic; Anders Wahlin; Hamdy Omar; Gunnar Juliusson; Eva Kimby; Hans Hagglund
• Department/s: Stem Cell Center; StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
• Publishing year: 2012
• Language: English
• Pages: 1699-1705
• Publication/Series: Leukemia & Lymphoma
• Volume: 53
• Issue: 9
• Links: http://dx.doi.org/10.3109/10428194.2012.666661
• Document type: Journal article
• Publisher: Taylor & Francis
• Topic: Cancer and Oncology
• Keywords: Allogeneic stem cell transplant; chronic lymphocytic leukemia; T-cell; donor engraftment
• Status: Published
• ISBN/ISSN/Other: ISSN: 1042-8194